Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2 clinical trials
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate

gilbert's syndrome
metastasis
fine-needle aspiration
formalin-fixed paraffin-embedded
solid tumor
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Patients will be treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable toxicity and/or as long as the investigator deems that the patient is benefiting from treatment.

ATM
small cell carcinoma of the prostate
gilbert's syndrome
enzalutamide
sipuleucel-t
  • 0 views
  • 16 Feb, 2024
  • 1 location